\
&
Contact us
\
&
Contact us
Published on | 4 years ago
Programmes NMBP Food Energy Transport Climate/Environment SwafS Green DealThe success rates for the EU Green Deal call for proposals can be found on our website in this document
The numbers are based on our own calculations and are merely for your information. For most calls we are not sure how many projects will be funded so we have used a minimum and a maximum amount to calculate the ratios.
For more information you can contact Pascal Verheye via pascal.verheye@vlaio.be
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
